NeuroSense's Participation at the 28th Annual H.C. Wainwright Global Investment Conference
NeuroSense Therapeutics Ltd., a pioneering clinical biotechnology firm listed under NASDAQ: NRSN, has announced its participation in the 28th Annual H.C. Wainwright Global Investment Conference, which will take place from September 14 to 16, 2026, in New York City. The company's management team is scheduled to deliver a significant corporate presentation on September 15 at 4:30 PM ET, outlining the recent advancements in their lead drug candidate, PrimeC, designed to treat amyotrophic lateral sclerosis (ALS).
NeuroSense's presentation will focus on the progress the company has made in clinical trials and regulatory submissions, particularly in preparation for the pivotal Phase 3 PARAGON trial. This trial is expected to play a crucial role in evaluating PrimeC's efficacy in treating ALS, a devastating neurodegenerative disease that leads to complete paralysis and fatality within a few years post-diagnosis. Each year, around 5,000 individuals are diagnosed with ALS in the U.S., underscoring the urgent need for effective treatments.
PrimeC is NeuroSense's innovative oral therapy, which represents a fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. This unique formulation targets several underlying biological pathways that contribute to neurodegeneration—such as neuroinflammation and oxidative stress—making it an exciting candidate in the quest to halt ALS progression. Recent analysis of long-term follow-up data from the Phase 2b PARADIGM study has demonstrated that PrimeC could potentially slow functional decline in ALS patients, as revealed by results published in the esteemed journal JAMA Neurology.
During the upcoming conference, NeuroSense's management team will be available for one-on-one meetings with institutional investors, allowing potential stakeholders to engage directly with the leadership on the company's strategic direction and clinical development plans. Investors interested in scheduling these meetings are encouraged to use the H.C. Wainwright conference platform or contact the NeuroSense investor relations team for assistance.
In the face of increasing diagnoses of ALS—projected to rise by 24% in the U.S. and EU by 2040—the significance of NeuroSense's work cannot be understated. ALS not only imposes a tremendous health burden on individuals and families but also on healthcare systems, with annual costs exceeding $1 billion in the U.S. alone. The company's commitment to developing disease-modifying therapies for ALS and Alzheimer's reflects its broader mission to offer hope and improved quality of life for those affected by neurodegenerative diseases.
For more detailed updates regarding NeuroSense's progress, insights from the management team during the conference, and a plethora of information on ongoing clinical trials, interested parties are encouraged to visit the company's dedicated website and follow their updates on various social media platforms including LinkedIn, YouTube, and X. The importance of keeping abreast of these developments is paramount for investors, as the outcomes of these trials may significantly influence market positions and therapeutic approaches for ALS.
NeuroSense remains at the forefront of innovation in biotechnology, and its participation at the H.C. Wainwright conference serves as a critical platform for advocating the advancement of PrimeC and the fight against ALS. The path to regulatory approval is fraught with challenges, yet NeuroSense is strategically positioned to navigate the intricacies of clinical development and bring forth a new therapeutic option in this desperately needed space.
NeuroSense's presentation will focus on the progress the company has made in clinical trials and regulatory submissions, particularly in preparation for the pivotal Phase 3 PARAGON trial. This trial is expected to play a crucial role in evaluating PrimeC's efficacy in treating ALS, a devastating neurodegenerative disease that leads to complete paralysis and fatality within a few years post-diagnosis. Each year, around 5,000 individuals are diagnosed with ALS in the U.S., underscoring the urgent need for effective treatments.
PrimeC is NeuroSense's innovative oral therapy, which represents a fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. This unique formulation targets several underlying biological pathways that contribute to neurodegeneration—such as neuroinflammation and oxidative stress—making it an exciting candidate in the quest to halt ALS progression. Recent analysis of long-term follow-up data from the Phase 2b PARADIGM study has demonstrated that PrimeC could potentially slow functional decline in ALS patients, as revealed by results published in the esteemed journal JAMA Neurology.
During the upcoming conference, NeuroSense's management team will be available for one-on-one meetings with institutional investors, allowing potential stakeholders to engage directly with the leadership on the company's strategic direction and clinical development plans. Investors interested in scheduling these meetings are encouraged to use the H.C. Wainwright conference platform or contact the NeuroSense investor relations team for assistance.
In the face of increasing diagnoses of ALS—projected to rise by 24% in the U.S. and EU by 2040—the significance of NeuroSense's work cannot be understated. ALS not only imposes a tremendous health burden on individuals and families but also on healthcare systems, with annual costs exceeding $1 billion in the U.S. alone. The company's commitment to developing disease-modifying therapies for ALS and Alzheimer's reflects its broader mission to offer hope and improved quality of life for those affected by neurodegenerative diseases.
For more detailed updates regarding NeuroSense's progress, insights from the management team during the conference, and a plethora of information on ongoing clinical trials, interested parties are encouraged to visit the company's dedicated website and follow their updates on various social media platforms including LinkedIn, YouTube, and X. The importance of keeping abreast of these developments is paramount for investors, as the outcomes of these trials may significantly influence market positions and therapeutic approaches for ALS.
NeuroSense remains at the forefront of innovation in biotechnology, and its participation at the H.C. Wainwright conference serves as a critical platform for advocating the advancement of PrimeC and the fight against ALS. The path to regulatory approval is fraught with challenges, yet NeuroSense is strategically positioned to navigate the intricacies of clinical development and bring forth a new therapeutic option in this desperately needed space.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.